Journal Cover Consumer Drugs
  [0 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 1530-1206
   Published by Informa plc Homepage  [9 journals]
  • OTC Oral Contraceptive Interest Could Be Price Sensitive, Study Suggests
    • Abstract: A survey with 2,026 women and 513 teens showed they are willing to pay out-of-pocket for the convenience of OTC...      Related Stories
      Supreme Court Ruling on ‘Plausibility’ In Landmark UK Lyrica Case Expected Early Summer
      EU Advocate General Sides With Pfizer Over Orifarm’s Parallel Importing Of Enbrel
      Opioid-Sparing Claims Should Meet High Bar, US FDA Panel Says 
      PubDate: Mon, 19 Feb 2018 14:05:00 GMT
       
  • More GRASE Time For 6 OTC Antiseptic Ingredients But 24 Flushed In Final
           Rule
    • Abstract: An FDA final rule rejects generally regarded as safe and effective status for 24 OTC monograph antiseptic ingredients regarding products...      Related Stories
      Supreme Court Ruling on ‘Plausibility’ In Landmark UK Lyrica Case Expected Early Summer
      EU Advocate General Sides With Pfizer Over Orifarm’s Parallel Importing Of Enbrel
      Opioid-Sparing Claims Should Meet High Bar, US FDA Panel Says 
      PubDate: Mon, 19 Feb 2018 00:02:01 GMT
       
  • FDA Broadens Nicotine Therapy Indication Review With Steering Committee
           Docket
    • Abstract: FDA seeks broader guidance than comments and information submitted at a January public hearing on standards testing and evaluations that...      Related Stories
      FDA And Industry Officials Tout Benefits Of Performance-Based Established Conditions In ICH Q12
      Agree A Brexit Transition By March Or See Pharma Waste Money On Contingency Plans, Says UK Cttee
      New EU Submissions For Pfizer’s Lorlatinib, Teva’s Fremanezumab - And A CV Filing For Canakinumab 
      PubDate: Fri, 16 Feb 2018 14:04:30 GMT
       
  • Mucinex Fast-Max Advertising Claim Exceeds Indications In NAD Review
    • Abstract: Review was second in two years by the Council of Better Business Bureaus? National Advertising Division of a challenge to...      Related Stories
      Agree A Brexit Transition By March Or See Pharma Waste Money On Contingency Plans, Says UK Cttee
      New EU Submissions For Pfizer’s Lorlatinib, Teva’s Fremanezumab - And A CV Filing For Canakinumab
      EU Firsts For CAR-T & PRIME As EMA Grants Kite Accelerated Assessment 
      PubDate: Wed, 14 Feb 2018 17:56:54 GMT
       
  • P&G Extends Gum Repair Toothpaste Line As It Trims Production
           Footprint
    • Abstract: P&G says harmful plaque bacteria below the gum line evades "even the most the diligent brushers." The firm plans in...      Related Stories
      WaterPik Whitening Flosser Launch Adds Shine To Church & Dwight Results
      Recent And Upcoming FDA Advisory Committee Meetings
      EMA Calls For Visual Warnings Among Measures To Restrict Valproate Use 
      PubDate: Fri, 09 Feb 2018 15:35:31 GMT
       
  • WaterPik Whitening Flosser Launch Adds Shine To Church & Dwight
           Results
    • Abstract: Firm says it also looks to grow WaterPik sales with investment in international channels. Water Pik subsidiary says Whitening Water...      Related Stories
      P&G Extends Gum Repair Toothpaste Line As It Trims Production Footprint
      Recent And Upcoming FDA Advisory Committee Meetings
      EMA Calls For Visual Warnings Among Measures To Restrict Valproate Use 
      PubDate: Fri, 09 Feb 2018 15:34:45 GMT
       
  • GSK Rides Cold, Flu And Pain OTCs In Q4 While Allergy Carries Sanofi
    • Abstract: Firm?s "power brands" in respiratory and pain areas achieved high single-digit sales growth in the fourth quarter on an “earlier...      Related Stories
      WaterPik Whitening Flosser Launch Adds Shine To Church & Dwight Results
      P&G Extends Gum Repair Toothpaste Line As It Trims Production Footprint
      Recent And Upcoming FDA Advisory Committee Meetings 
      PubDate: Thu, 08 Feb 2018 18:01:31 GMT
       
  • Senate OTC Monograph Bill Boosts Industry Hopes For Passage This Year
    • Abstract: Senate legislation to reform the US OTC monograph process mirrors the House draft proposed in January, including a two-year market...      Related Stories
      EMA Rejection For Raxone Plunges UK Early Access Scheme Into Uncharted Territory
      Another Knockback For Roche And Novartis As CJEU Rules On Italian Competition Case
      EMA’s Revised ATMP Evaluation Procedure Gets Industry Thumbs Up 
      PubDate: Tue, 06 Feb 2018 17:00:30 GMT
       
  • Prestige Brands' Costs Grow With OTC Portfolio, But Retailer
           Orders Slow
    • Abstract: Consumer products firm?s execs also expect "destocking" by drug, grocery and mass merchandise chains and other retail businesses to give...      Related Stories
      Lack Of Comparative Trials Stymied BMS’s EU Filings For Opdivo In Colorectal, Liver Cancers
      Ireland Fears Shortage Of Medicines Co-Labeled With UK Following Brexit
      FDA Reviewers Share CMC, GMP Challenges In Last Year?s Rush To Approve New Therapies 
      PubDate: Mon, 05 Feb 2018 16:57:28 GMT
       
  • FDA Looks At OTC Loperamide Packaging To Curb Opioid-Related Abuse
    • Abstract: Ingredient in J&J?s Imodium and numerous OTC generics acts on opioid receptors in the gut to slow movement in the...      Related Stories
      Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD Review
      Hemlibra Patent Dispute Spills Over Into Patient Community
      FDA?s NDA And BLA Approvals: Abilify Mycite, Mepsevii, Hemlibra 
      PubDate: Fri, 02 Feb 2018 17:23:01 GMT
       
  • Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD
           Review
    • Abstract: Claims that Sanofi?s Xyzal 24 HR OTC product contains the same effectiveness as competitor Zyrtec but with half the medication...      Related Stories
      Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD Review
      Hemlibra Patent Dispute Spills Over Into Patient Community
      FDA?s NDA And BLA Approvals: Abilify Mycite, Mepsevii, Hemlibra 
      PubDate: Fri, 02 Feb 2018 14:48:09 GMT
       
  • Pfizer Mum On Consumer Business Plans As Analysts Say Spin-off
    • Abstract: Pfizer continues to review options for its consumer business, though analysts say a spin-off makes most sense. During its fourth-quarter...      Related Stories
      Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD Review
      Hemlibra Patent Dispute Spills Over Into Patient Community
      FDA?s NDA And BLA Approvals: Abilify Mycite, Mepsevii, Hemlibra 
      PubDate: Thu, 01 Feb 2018 15:23:02 GMT
       
  • Emotional Backdrop Smolders As FDA Reviews Smoking Cessation Category
    • Abstract: FDA asks for comments including evidence needed to show safety and efficacy for novel nicotine replacement therapies, but speakers at...      Related Stories
      Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD Review
      Hemlibra Patent Dispute Spills Over Into Patient Community
      FDA?s NDA And BLA Approvals: Abilify Mycite, Mepsevii, Hemlibra 
      PubDate: Wed, 31 Jan 2018 14:06:16 GMT
       
  • GSK Consumer Tries On Wearable Pain Relief With NeuroMetrix Deal
    • Abstract: GSK Consumer purchases ex-US rights to pain relief device Quell from NeuroMetrix in a deal that includes co-development of transcutaneous...      Related Stories
      Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD Review
      Hemlibra Patent Dispute Spills Over Into Patient Community
      FDA?s NDA And BLA Approvals: Abilify Mycite, Mepsevii, Hemlibra 
      PubDate: Mon, 29 Jan 2018 16:33:47 GMT
       
  • Colgate Boosts Ad Spending Again After Organic Growth Falls Short
    • Abstract: Colgate CEO Ian Cook expects brand investments will help boost organic sales 3%-5% in 2018. However, the firm?s 24% increase...      Related Stories
      Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD Review
      Hemlibra Patent Dispute Spills Over Into Patient Community
      FDA?s NDA And BLA Approvals: Abilify Mycite, Mepsevii, Hemlibra 
      PubDate: Sun, 28 Jan 2018 22:28:20 GMT
       
  • J&J Consumer Makes 'Aggressive' Shift In Digital
           Sales To Drive Growth
    • Abstract: When J&J CEO Gorsky says, "We?re not just sitting back, we?re making aggressive moves in areas such as e-commerce, investments...      Related Stories
      Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD Review
      Hemlibra Patent Dispute Spills Over Into Patient Community
      FDA?s NDA And BLA Approvals: Abilify Mycite, Mepsevii, Hemlibra 
      PubDate: Thu, 25 Jan 2018 19:02:04 GMT
       
  • P&G Stretches ZzzQuil Sleep Brand Into Supplement Space With
           PureZzzs
    • Abstract: P&G will launch Vicks ZzzQuil PureZzzs in late February as a drug-free, melatonin-based sleep aid, CFO Jon Moeller says. P&G...      Related Stories
      Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD Review
      Hemlibra Patent Dispute Spills Over Into Patient Community
      FDA?s NDA And BLA Approvals: Abilify Mycite, Mepsevii, Hemlibra 
      PubDate: Wed, 24 Jan 2018 19:43:01 GMT
       
  • Pharmacists Stall Turkey's Launch Of Regulated Consumer Health
           Market
    • Abstract: Turkish regulators published a list of 241 products, based on 62 ingredients, selected to become available nonprescription but withdrew it...      Related Stories
      Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD Review
      Hemlibra Patent Dispute Spills Over Into Patient Community
      FDA?s NDA And BLA Approvals: Abilify Mycite, Mepsevii, Hemlibra 
      PubDate: Mon, 22 Jan 2018 09:03:05 GMT
       
  • Viewpoints Cover The Waterfront At FDA Nicotine Replacement Therapy Policy
           Hearing
    • Abstract: FDA added to the docket for its initiative evaluating nicotine replacement therapies reference materials including a meta-analysis on efficacy of...      Related Stories
      Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD Review
      Hemlibra Patent Dispute Spills Over Into Patient Community
      FDA?s NDA And BLA Approvals: Abilify Mycite, Mepsevii, Hemlibra 
      PubDate: Fri, 19 Jan 2018 19:03:40 GMT
       
  • Entrepreneur Davies Enters Consumer Health With Indian Research Support
    • Abstract: UK generics firm Neolab founder and serial entrepreneur John Davies outlines his latest product development efforts, targeting the consumer health...      Related Stories
      Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD Review
      Hemlibra Patent Dispute Spills Over Into Patient Community
      FDA?s NDA And BLA Approvals: Abilify Mycite, Mepsevii, Hemlibra 
      PubDate: Fri, 19 Jan 2018 12:13:10 GMT
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.90.119.59
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-